These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 16027521)

  • 1. Prospective evaluation of renal function in pediatric and adult patients treated with high-dose ifosfamide, cisplatin and high-dose methotrexate.
    Ferrari S; Pieretti F; Verri E; Tolentinis L; Cesari M; Versari M; Zolezzi C; Lamanna G; Bacci G
    Anticancer Drugs; 2005 Aug; 16(7):733-8. PubMed ID: 16027521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective evaluation of high-dose ifosfamide-related nephrotoxicity in young adult patients with recurrent osteosarcoma previously treated with cisplatin, methotrexate and standard-dose ifosfamide.
    Ferrari S; Zolezzi C; Cesari M; Fasano MC; Lamanna G; Bacci G
    Anticancer Drugs; 1999 Jan; 10(1):25-31. PubMed ID: 10194544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal function following combination chemotherapy with ifosfamide and cisplatin in patients with osteogenic sarcoma.
    Arndt C; Morgenstern B; Hawkins D; Wilson D; Liedtke R; Miser J
    Med Pediatr Oncol; 1999 Feb; 32(2):93-6. PubMed ID: 9950195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG/OS-1.
    Ferrari S; Ruggieri P; Cefalo G; Tamburini A; Capanna R; Fagioli F; Comandone A; Bertulli R; Bisogno G; Palmerini E; Alberghini M; Parafioriti A; Linari A; Picci P; Bacci G
    J Clin Oncol; 2012 Jun; 30(17):2112-8. PubMed ID: 22564997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term nephrotoxicity of cisplatin, ifosfamide, and methotrexate in osteosarcoma.
    Koch Nogueira PC; Hadj-Aïssa A; Schell M; Dubourg L; Brunat-Mentigny M; Cochat P
    Pediatr Nephrol; 1998 Sep; 12(7):572-5. PubMed ID: 9761357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonmetastatic osteosarcoma of the extremity. Neoadjuvant chemotherapy with methotrexate, cisplatin, doxorubicin and ifosfamide. An Italian Sarcoma Group study (ISG/OS-Oss).
    Ferrari S; Meazza C; Palmerini E; Tamburini A; Fagioli F; Cozza R; Ferraresi V; Bisogno G; Mascarin M; Cefalo G; Manfrini M; Capanna R; Biagini R; Donati D; Picci P
    Tumori; 2014; 100(6):612-9. PubMed ID: 25688494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative outcome of Thai pediatric osteosarcoma treated with two protocols: the role of high-dose methotrexate (HDMTX) in a single institute experience.
    Choeyprasert W; Pakakasama S; Sirachainan N; Songdej D; Chuansumrit A; Anurathapan U; Hongeng S; Nartthanarung A
    Asian Pac J Cancer Prev; 2014; 15(22):9823-9. PubMed ID: 25520112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delayed methotrexate clearance in osteosarcoma patients treated with multiagent regimens of neoadjuvant chemotherapy.
    Bacci G; Ferrari S; Longhi A; Forni C; Loro L; Beghelli C; Tremosini M; Versari M
    Oncol Rep; 2003; 10(4):851-7. PubMed ID: 12792734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups.
    Ferrari S; Smeland S; Mercuri M; Bertoni F; Longhi A; Ruggieri P; Alvegard TA; Picci P; Capanna R; Bernini G; Müller C; Tienghi A; Wiebe T; Comandone A; Böhling T; Del Prever AB; Brosjö O; Bacci G; Saeter G;
    J Clin Oncol; 2005 Dec; 23(34):8845-52. PubMed ID: 16246977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Highly effective reduced toxicity dose-intensive pilot protocol for non-metastatic limb osteogenic sarcoma (SCOS 89).
    Shkalim-Zemer V; Ash S; Toledano H; Kollender Y; Issakov J; Yaniv I; Cohen IJ
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):909-16. PubMed ID: 26365289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sex- and age-related chemotherapy toxicity in patients with non-metastatic osteosarcoma.
    Ferrari S; Palmerini E; Staals E; Abate ME; Longhi A; Cesari M; Balladelli A; Pratelli L; Bacci G
    J Chemother; 2009 Apr; 21(2):205-10. PubMed ID: 19423475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pantoprazole, an Inhibitor of the Organic Cation Transporter 2, Does Not Ameliorate Cisplatin-Related Ototoxicity or Nephrotoxicity in Children and Adolescents with Newly Diagnosed Osteosarcoma Treated with Methotrexate, Doxorubicin, and Cisplatin.
    Fox E; Levin K; Zhu Y; Segers B; Balamuth N; Womer R; Bagatell R; Balis F
    Oncologist; 2018 Jul; 23(7):762-e79. PubMed ID: 29445029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose intensity of chemotherapy for osteosarcoma and outcome in the Cooperative Osteosarcoma Study Group (COSS) trials.
    Eselgrim M; Grunert H; Kühne T; Zoubek A; Kevric M; Bürger H; Jürgens H; Mayer-Steinacker R; Gosheger G; Bielack SS
    Pediatr Blood Cancer; 2006 Jul; 47(1):42-50. PubMed ID: 16206218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fertility in male patients treated with neoadjuvant chemotherapy for osteosarcoma.
    Longhi A; Macchiagodena M; Vitali G; Bacci G
    J Pediatr Hematol Oncol; 2003 Apr; 25(4):292-6. PubMed ID: 12679642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A prospective study on nephrotoxicity induced by continuous infusion of high-dose ifosfamide (15/m2)].
    Ferrari S; Zolezzi C; Bacci G; Pieretti F; Iantorno D; Figus E; Pizzoferrato A
    Minerva Pediatr; 1997; 49(1-2):29-37. PubMed ID: 9132558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant and adjuvant chemotherapy with high-dose ifosfamide, doxorubicin, cisplatin and high-dose methotrexate in non-metastatic osteosarcoma of the extremities: a phase II trial in Japan.
    Kudawara I; Aoki Y; Ueda T; Araki N; Naka N; Nakanishi H; Matsumine A; Ieguchi M; Mori S; Myoui A; Kuratsu S; Hashimoto N; Yoshikawa H
    J Chemother; 2013 Feb; 25(1):41-8. PubMed ID: 23433444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate.
    Meyers PA; Schwartz CL; Krailo M; Kleinerman ES; Betcher D; Bernstein ML; Conrad E; Ferguson W; Gebhardt M; Goorin AM; Harris MB; Healey J; Huvos A; Link M; Montebello J; Nadel H; Nieder M; Sato J; Siegal G; Weiner M; Wells R; Wold L; Womer R; Grier H
    J Clin Oncol; 2005 Mar; 23(9):2004-11. PubMed ID: 15774791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma.
    Crews KR; Liu T; Rodriguez-Galindo C; Tan M; Meyer WH; Panetta JC; Link MP; Daw NC
    Cancer; 2004 Apr; 100(8):1724-33. PubMed ID: 15073863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant chemotherapy for osteosarcoma of the extremities with synchronous lung metastases: treatment with cisplatin, adriamycin and high dose of methotrexate and ifosfamide.
    Bacci G; Briccoli A; Ferrari S; Saeter G; Donati D; Longhi A; Manfrini M; Bertoni F; Rimondini S; Monti C; Forni C
    Oncol Rep; 2000; 7(2):339-46. PubMed ID: 10671683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of large osteosarcoma in children: new approach.
    Kobys VL; Konovalenko VF; Repinа NV; Golovko TS; Gulak LO; Tarasova TO; Zaharycheva EV; Matyushok OF
    Exp Oncol; 2013 Jun; 35(2):105-8. PubMed ID: 23828385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.